Results 21 to 30 of about 164,596 (212)

FAM83B inhibits ovarian cancer cisplatin resistance through inhibiting Wnt pathway

Oncogenesis, 2021
Cisplatin resistance is frequently occurred in ovarian cancer therapy, understanding its regulatory mechanisms is critical for developing novel treatment methods and drugs.
Shanyang He, Wei Wang, Zhiyong Wan, Hongwei Shen, Yunhe Zhao, Zeshan You, Jun Liu, Liwen Zhu   +7 more
doaj   +1 more source

The Role of Tumour Metabolism in Cisplatin Resistance

Frontiers in Molecular Biosciences, 2021
Cisplatin is a chemotherapy drug commonly used in cancer treatment. Tumour cells are more sensitive to cisplatin than normal cells. Cisplatin exerts an antitumour effect by interfering with DNA replication and transcription processes.
Lude Wang, Xiaoya Zhao, Jianfei Fu, Wenxia Xu, Jianlie Yuan   +4 more
doaj   +1 more source

Mitochondrial Involvement in Cisplatin Resistance [PDF]

International Journal of Molecular Sciences, 2019
Cisplatin is one of the worldwide anticancer drugs and, despite its toxicity and frequent recurrence of resistance phenomena, it still remains the only therapeutic option for several tumors. Circumventing cisplatin resistance remains, therefore, a major goal for clinical therapy and represents a challenge for scientific research.
Veronica Cocetta, Eugenio Ragazzi, Monica Montopoli   +2 more
openaire   +3 more sources

Eukaryotic initiation factor 5A2 mediates hypoxia-induced autophagy and cisplatin resistance

Cell Death and Disease, 2022
Hypoxia-induced cisplatin resistance is a major challenge during non-small cell lung cancer (NSCLC) treatment. Based on previous studies, we further explored the effect of eukaryotic initiation factor 5A2 (eIF5A2) in hypoxia-induced cisplatin resistance.
Guodong Xu, Hang Chen, Shibo Wu, Jiabin Chen, Shufen Zhang, Guofeng Shao, Lebo Sun, Yinyu Mu, Kaitai Liu, Qiaoling Pan, Ni Li, Xiaoxia An, Shuang Lin, Wei Chen   +13 more
doaj   +1 more source

Molecular mechanisms of cisplatin resistance [PDF]

Oncogene, 2011
Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers.
L, Galluzzi, L, Senovilla, I, Vitale, J, Michels, I, Martins, O, Kepp, M, Castedo, G, Kroemer   +7 more
openaire   +2 more sources

Cemiplimab for Cisplatin Resistant Metastatic Penile Cancer [PDF]

Case Reports in Oncology, 2021
We report on a 75-year old man who presented with metastatic, squamous-cell carcinoma (SCC) of the penis whose disease had progressed after radiotherapy (RT) and cisplatin-based chemotherapy (CT). A strong PD-L1 expression as well as a CDKN2A mutation was documented, and he was given cemiplimab every 3 weeks at time of disease progression.
Denis, Chloé, Sakalihasan, Sarah, FRERES, Pierre, WITHOFS, Nadia, SAUTOIS, Brieuc   +4 more
openaire   +3 more sources

Cisplatin induces resistance by triggering differentiation of testicular embryonal carcinoma cells. [PDF]

PLoS ONE, 2014
Although testicular germ cell tumors are generally quite responsive to treatment with cisplatin, a small fraction of them acquire resistance during therapy. Even when cisplatin treatment is successful the patient is often left with a residual teratoma at
Paolo B Abada, Stephen B Howell
doaj   +1 more source

Downregulation of VPS13C promotes cisplatin resistance in cervical cancer by upregulating GSTP1

iScience, 2023
Summary: Cisplatin resistance remains a major obstacle limiting the effectiveness of chemotherapy in cervical cancer. However, the underlying mechanism of cisplatin resistance is still unclear.
Xiangyu Tan, Xueqian Wang, Xueyao Liao, Xin Wang, Zhichao Jiang, Wenjia Liang, Chen Cao, Danni Gong, Zheng Hu, Xun Tian   +9 more
doaj   +1 more source

Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells [PDF]

, 2006
Cisplatin produces good responses in solid tumours including small cell lung cancer (SCLC) but this is limited by the development of resistance. Oxaliplatin is reported to show activity against some cisplatin-resistant cancers but there is little known ...
A Ibrahim, A Rennicke, AB Sandler, AP Jekunen, BA Jansen, BA Teicher, Britta K. Stordal, BS Burns, C Kollmannsberger, C Kollmannsberger, CR Culy, D Pectasides, D Pectasides, DC Marks, G Belvedere, G Lenz, G Tisman, GA Hospers, H Kawai, H Kuroda, HD Preisler, HD Preisler, IS Song, J Liu, JM Woynarowski, JM Woynarowski, K Suzukake, K Yamamoto, KV Grech, L Pendyala, L Poulain, M Abal, M Markman, M Mishima, Mary W. Davey, N Jain, N Savaraj, N Thatcher, O Rixe, P Chollet, P Soulie, PJ Kuppen, PR Twentyman, R Sockalingam, RD Christen, Ross A. Davey, S Hector, S Ohta, SG Chaney, SL Lai, SW Johnson, T Fojo, T Moritaka, T Tashiro, V Dieras, VL Locke, WS Hong, Z El Akawi, Z Wang   +58 more
core   +2 more sources

Literature Review: Mekanisme Resistensi Kemoterapi Berbasis Platinum

Jurnal Kesehatan, 2020
Cisplatin is a type of platinum-based chemotherapy that is often used in the spectrum of solid neoplasms, including the ovaries, testicles, urinary vesicles, colorectal, lungs, and head-neck.
Amelia Rizky Khalidah
doaj   +1 more source